REG - SkinBioTherapeutics - Update regarding Nominated Adviser and Broker

SkinbiotherapeuticsAnnouncement

22/11/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231122:nRSV2069Ua&default-theme=true

RNS Number : 2069U  SkinBioTherapeutics PLC  22 November 2023

22 November 2023

 

 

 

SkinBioTherapeutics plc

 

("SkinBioTherapeutics" or "the Company")

 

Update regarding Nominated Adviser and Broker

 

SkinBioTherapeutics plc, (AIM: SBTX, or the "Company"), the life science
business focused on skin health, announces that, following the completion of
the all-share merger between Cavendish Securities plc (previously named Cenkos
Securities plc) and Cavendish Financial plc (previously named finnCap Group
plc), and as a consequence of internal reorganisation within the Cavendish
Group, the Company has changed its Nominated Adviser and Broker from Cavendish
Securities plc to Cavendish Capital Markets Limited.

 

 

For more information please contact:

 SkinBioTherapeutics plc                             Tel: +44 (0) 191 495 7325

 Stuart J. Ashman, CEO

 Manprit Randhawa, CFO

 Cavendish Capital Markets Limited                                    Tel: +44 (0) 20 7220 0500

 (Nominated Adviser & Broker)

 Giles Balleny, Dan Hodkinson (Corporate Finance)

 Charlie Combe (Broking)

 Dale Bellis, Tamar Cranford-Smith (Sales)

 Instinctif Partners (financial press)               Tel: +44 (0) 20 7457 2020

 Melanie Toyne-Sewell / Adam Loudon / Jack Kincade   SkinBioT (mailto:SkinBio@instinctif.com) herapeutics@instinctif.com

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The
Company's proprietary platform technology, SkinBiotix®, is based upon
discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

The Company is targeting a number of skin healthcare sectors, the most
advanced of which are cosmetic skincare and food supplements to modulate the
immune system by harnessing the gut-skin axis. In each area
SkinBioTherapeutics plans to exemplify its technology through human studies.
The Company's first product, AxisBiotix-Ps™, a food supplement to address
the symptoms of mild to moderate psoriasis.

The Company listed on AIM in April 2017 and is based in Newcastle, UK.  For
more information, visit: www.skinbiotherapeutics.com
(http://www.skinbiotherapeutics.com/)  and www.axisbiotix.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPFFFELLILLFIV